What is LifeMD's operating income?

LifeMD's total operating income in 2024 was -$16.14 million, based on the following breakdown: Total Gross Profit: $188.39 million Total Operating Expenses: $204.53 million

LifeMD (LFMD) Financials

$4.73 +0.04 (+0.85%)

Closing price 07/9/2026 04:00 PM Eastern

Extended Trading

$4.86 +0.13 (+2.73%)

As of 04:00 AM Eastern

Compare

Annual Income Statements for LifeMD

This table shows LifeMD's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-0.46	-0.06	-1.11	-1.21	-1.24	-3.14	-63	-62	-49	-24	-22
Consolidated Net Income / (Loss)	-0.46	-0.16	-1.22	-1.22	-1.36	-3.53	-61	-61	-45	-18	-19
Net Income / (Loss) Continuing Operations	-0.56	-0.16	-1.22	-1.38	-2.29	-3.53	-61	-61	-45	-18	-19
Total Pre-Tax Income	-0.48	-0.17	-1.22	-1.38	-2.41	-3.65	-60	-61	-45	-17	-18
Total Operating Income	-0.53	-0.26	-1.17	-1.23	-2.06	-2.89	-58	-54	-43	-14	-16
Total Gross Profit	0.54	0.97	2.05	1.58	6.33	9.94	28	75	100	134	188
Total Revenue	0.71	1.22	5.24	3.68	8.32	12	37	93	119	153	212
Operating Revenue	0.71	1.22	5.24	3.68	8.32	12	37	93	119	153	212
Total Cost of Revenue	0.17	0.25	3.19	2.11	2.00	2.53	8.86	18	19	19	24
Operating Cost of Revenue	0.17	0.25	3.19	2.11	2.00	2.53	8.86	18	19	19	24
Total Operating Expenses	1.07	1.23	3.22	2.80	8.38	13	86	129	144	148	205
Selling, General & Admin Expense	0.46	0.45	1.51	1.16	2.81	3.69	47	46	59	66	92
Marketing Expense	0.06	0.23	1.71	1.64	5.08	8.92	39	83	78	76	103
Research & Development Expense	0.00	0.02	-	-	0.12	0.22	0.45	0.95	2.97	6.06	9.51
Total Other Income / (Expense), net	-0.05	0.09	-0.05	-0.15	-0.35	-0.76	-2.58	-7.02	-1.21	-2.92	-2.18
Interest Expense	0.00	0.04	0.05	0.65	0.35	0.00	2.58	3.02	1.21	2.92	2.18
Income Tax Expense	-0.02	-0.01	-	0.00	-0.12	-0.12	0.12	0.01	0.36	0.43	0.40
Preferred Stock Dividends Declared	-	-	-	-	-	0.00	4.72	0.87	3.11	3.11	3.11
Net Income / (Loss) Attributable to Noncontrolling Interest	0.00	-0.10	-0.12	-0.01	-0.12	-0.39	-1.88	-0.43	0.51	2.76	0.15
Weighted Average Basic Shares Outstanding	30.37M	30.81M	33.48M	41.74M	44.19M	9.90M	14.28M	27.01M	30.98M	33.91M	41.20M
Weighted Average Diluted Shares Outstanding	30.37M	30.81M	33.48M	41.74M	44.19M	9.90M	14.28M	27.01M	30.98M	33.91M	41.20M
Weighted Average Basic & Diluted Shares Outstanding	30.37M	30.81M	36.90M	41.74M	46.88M	54.14M	25.91M	30.83M	31.89M	40.37M	44.58M

This table shows LifeMD's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-6.90	-4.51	-7.54	-7.65	-5.43	-0.88	-0.96	-2.85	-4.58	-9.65
Consolidated Net Income / (Loss)	-5.28	-3.22	-6.65	-6.84	-4.79	0.23	0.35	-1.57	-3.56	-8.87
Net Income / (Loss) Continuing Operations	-5.28	-3.22	-6.65	-6.84	-4.79	0.23	-1.65	-1.57	-3.56	-8.87
Total Pre-Tax Income	-5.28	-2.79	-6.65	-6.84	-4.55	0.40	-1.65	-1.57	-3.39	-8.87
Total Operating Income	-4.57	-2.17	-6.17	-6.31	-4.00	1.02	-1.18	-0.91	-1.97	-8.93
Total Gross Profit	34	40	40	46	48	55	43	55	53	44
Total Revenue	39	45	44	51	53	64	51	62	60	50
Operating Revenue	39	45	44	51	53	64	51	62	60	50
Total Cost of Revenue	4.78	5.36	4.60	5.02	5.01	9.43	8.14	7.43	7.41	5.93
Operating Cost of Revenue	4.78	5.36	4.60	5.02	5.01	9.43	8.14	7.43	7.41	5.93
Total Operating Expenses	38	42	46	52	52	54	44	56	55	53
Selling, General & Admin Expense	17	19	19	23	23	26	20	24	22	21
Marketing Expense	20	20	24	26	27	26	22	29	29	30
Research & Development Expense	1.50	2.00	2.09	2.40	2.61	2.41	1.86	2.74	2.85	1.80
Total Other Income / (Expense), net	-0.71	-0.62	-0.48	-0.53	-0.56	-0.61	-0.46	-0.66	-1.42	0.06
Interest Expense	0.71	0.62	0.48	0.53	0.56	0.61	0.46	0.66	1.42	-0.06
Income Tax Expense	0.00	-	-	-	0.23	-	0.00	-	0.17	0.00
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	1.99	-	-	0.00
Preferred Stock Dividends Declared	0.78	0.78	0.78	0.78	0.78	0.78	0.78	0.78	0.78	0.78
Net Income / (Loss) Attributable to Noncontrolling Interest	0.84	0.51	0.12	0.04	-0.13	0.34	0.53	0.51	0.25	0.00
Basic Earnings per Share	-	-	-	-	-	-	($0.02)	-	-	($0.20)
Weighted Average Basic Shares Outstanding	34.47M	33.91M	39.24M	41.30M	42.02M	41.20M	43.14M	44.40M	46.16M	47.34M
Diluted Earnings per Share	-	-	-	-	-	-	($0.02)	-	-	($0.20)
Weighted Average Diluted Shares Outstanding	34.47M	33.91M	39.24M	41.30M	42.02M	41.20M	43.14M	44.40M	46.16M	47.34M
Weighted Average Basic & Diluted Shares Outstanding	37.98M	40.37M	42.29M	43.07M	43.31M	44.58M	45.45M	47.42M	48.14M	48.36M

This table details how cash moves in and out of LifeMD's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-0.08	0.16	-0.05	-0.04	0.04	0.21	8.07	32	-37	29	1.86
Net Cash From Operating Activities	0.03	-0.30	-0.41	-0.82	-0.91	0.25	-12	-33	-23	8.82	18
Net Cash From Continuing Operating Activities	0.03	-0.30	-0.41	-0.82	-0.87	0.24	-12	-33	-23	8.82	18
Net Income / (Loss) Continuing Operations	-0.46	-0.16	-1.22	-1.22	-1.36	-3.53	-61	-61	-45	-18	-19
Consolidated Net Income / (Loss)	-0.46	-0.16	-1.22	-1.22	-1.36	-3.53	-61	-61	-45	-18	-19
Depreciation Expense	0.06	0.04	-	0.00	-	-	0.00	0.01	0.16	0.20	0.49
Amortization Expense	-	0.00	0.03	0.09	0.51	0.96	1.21	2.95	3.61	6.73	9.41
Non-Cash Adjustments To Reconcile Net Income	0.26	0.00	0.66	1.49	0.22	0.64	38	17	25	14	14
Changes in Operating Assets and Liabilities, net	0.18	-0.18	0.12	-1.18	-0.24	2.18	9.46	8.52	-6.37	5.27	12
Net Cash From Investing Activities	0.00	0.13	0.00	0.00	0.14	-0.10	-0.80	-3.40	-14	-8.73	-12
Net Cash From Continuing Investing Activities	0.00	0.13	0.00	0.00	0.14	-0.10	-0.80	-3.40	-14	-8.73	-12
Purchase of Property, Plant & Equipment	-	-	-	-	-	-	0.00	-0.25	-0.37	-0.20	-1.49
Acquisitions	-	-	-	0.00	-0.25	0.00	-0.40	-3.15	-14	-8.53	-10
Net Cash From Financing Activities	-0.11	0.33	0.36	0.78	0.80	0.78	21	69	-0.53	29	-4.12
Net Cash From Continuing Financing Activities	-0.11	0.33	0.36	0.78	0.80	0.08	21	69	-0.53	29	-4.12
Repayment of Debt	-0.08	-0.15	-0.17	-0.76	-0.23	-0.58	-2.51	-16	-0.17	-5.14	-0.33
Payment of Dividends	0.00	0.18	0.22	0.06	0.16	-0.09	-0.16	-1.02	-3.25	-3.25	-3.88
Issuance of Debt	0.07	0.31	0.30	0.88	0.88	1.09	2.59	16	2.91	22	0.00
Issuance of Common Equity	-	-	-	0.67	0.00	0.35	17	14	0.00	16	0.00
Other Financing Activities, net	-0.10	0.00	0.09	0.00	0.00	0.00	0.93	0.85	-0.02	-0.52	0.09
Cash Interest Paid	0.00	0.03	0.01	0.00	0.00	0.08	1.67	0.44	0.19	2.15	2.53

This table details how cash moves in and out of LifeMD's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Net Change in Cash & Equivalents	3.38	18	1.96	0.59	1.88	-2.58	-0.61	1.83	-12	-2.31
Net Cash From Operating Activities	1.08	5.71	5.20	4.54	6.70	1.57	3.07	8.64	-0.15	0.44
Net Cash From Continuing Operating Activities	1.08	5.71	5.20	4.54	6.70	1.57	0.26	8.64	-0.15	0.44
Net Income / (Loss) Continuing Operations	-5.28	-3.22	-6.65	-6.84	-2.75	0.23	1.65	-1.57	-4.67	8.87
Consolidated Net Income / (Loss)	-5.28	-3.22	-6.65	-6.84	-2.75	0.23	0.35	-1.57	-4.67	-8.87
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	1.99	-	-	0.00
Depreciation Expense	0.05	0.06	0.07	0.10	0.15	0.17	0.16	0.18	0.26	0.29
Amortization Expense	1.76	1.98	2.13	2.28	2.51	2.48	1.64	2.74	2.76	1.71
Non-Cash Adjustments To Reconcile Net Income	4.18	4.05	2.96	4.55	2.51	4.12	2.82	2.12	5.01	1.65
Changes in Operating Assets and Liabilities, net	0.36	2.85	6.69	4.44	4.28	-5.44	-2.71	5.17	-3.51	5.67
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	2.81	-	-	0.00
Net Cash From Investing Activities	-2.40	-2.22	-2.19	-3.13	-3.49	-2.72	-2.87	-3.70	-3.59	-2.06
Net Cash From Continuing Investing Activities	-2.40	-2.22	-2.19	-3.13	-3.49	-2.72	-2.00	-3.70	-3.59	-2.06
Purchase of Property, Plant & Equipment	-0.03	-0.11	-0.18	-0.64	-0.45	-0.23	-0.12	-0.80	-0.80	-0.11
Acquisitions	-2.37	-2.11	-2.01	-2.49	-3.05	-2.50	-1.89	-2.90	-2.80	-1.95
Net Cash From Discontinued Investing Activities	-	-	-	-	-	-	-0.86	-	-	0.00
Net Cash From Financing Activities	4.71	14	-1.05	-0.82	-1.32	-1.43	-0.81	-3.10	-8.70	-0.70
Net Cash From Continuing Financing Activities	4.71	14	-1.05	-0.82	-1.32	-1.43	-0.78	-3.10	-8.70	-0.70
Payment of Dividends	-0.81	-0.81	-0.81	-0.81	-1.31	-1.44	-0.78	-1.05	-1.23	-0.78
Other Financing Activities, net	-0.06	-0.03	-0.02	0.10	-	0.01	0.00	-	0.47	0.08
Net Cash From Discontinued Financing Activities	-	-	-	-	-	-	-0.04	-	-	0.00
Cash Interest Paid	0.72	0.66	0.64	0.64	0.63	0.61	0.59	0.63	0.24	0.00
Cash Income Taxes Paid	-	-	-	-	-	-	0.02	-	-	0.00

This table presents LifeMD's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	0.45	0.79	1.26	2.62	3.45	13	50	26	58	76	70
Total Current Assets	0.45	0.79	1.26	1.61	2.75	12	45	11	43	52	52
Cash & Equivalents	0.23	0.18	0.14	0.18	1.11	9.18	41	3.96	33	35	37
Accounts Receivable	0.15	0.45	0.13	0.10	0.10	1.00	0.98	2.83	5.28	11	9.31
Inventories, net	0.06	0.16	0.68	1.02	0.95	1.26	1.62	3.70	2.76	2.80	2.77
Other Current Assets	-	0.00	0.02	0.30	0.59	0.97	1.00	0.81	1.42	3.71	2.97
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.23	0.48	0.48	1.48	2.44
Total Noncurrent Assets	0.00	0.00	0.00	1.01	0.70	0.99	4.77	14	15	22	16
Intangible Assets	-	-	0.00	1.01	0.68	0.72	3.02	13	15	16	11
Other Noncurrent Operating Assets	-	-	-	0.00	0.02	0.27	1.75	1.21	0.59	6.40	5.27
Total Liabilities & Shareholders' Equity	0.45	0.79	1.26	2.62	3.45	13	50	26	58	76	70
Total Liabilities	0.27	1.15	0.64	1.80	4.58	14	24	33	53	84	47
Total Current Liabilities	0.27	1.15	0.64	1.19	3.98	14	23	31	35	67	42
Accounts Payable	0.17	0.75	0.42	0.87	3.05	12	9.06	10	11	16	14
Accrued Expenses	-	-	-	-	-	-	12	12	14	23	16
Current Deferred Revenue	-	-	0.00	0.08	0.11	0.92	1.50	5.55	8.83	20	11
Other Current Liabilities	-	0.19	-	-	-	0.09	0.61	0.76	0.60	0.51	0.64
Total Noncurrent Liabilities	0.00	0.00	0.00	0.60	0.60	0.29	1.28	1.60	18	16	5.68
Other Noncurrent Operating Liabilities	-	-	0.00	0.60	0.53	0.29	1.28	1.60	0.21	6.37	5.68
Commitments & Contingencies	-	-	-	-	0.00	-	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.18	-0.36	0.62	0.82	-1.13	-4.48	22	-12	5.57	-7.55	23
Total Preferred & Common Equity	0.10	-0.36	0.88	0.90	-0.99	-2.30	23	-11	3.51	-9.08	23
Preferred Stock	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	0.10	-0.36	0.88	0.90	-0.99	-2.30	23	-11	3.51	-9.08	23
Common Stock	8.69	9.43	12	13	16	78	165	179	218	231	252
Retained Earnings	-8.59	-9.69	-11	-12	-17	-80	-142	-191	-214	-240	-229
Treasury Stock	0.00	-0.09	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16

This table presents LifeMD's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	41	61	64	73	74	74	66	70
Total Current Assets	25	44	45	49	50	49	41	52
Cash & Equivalents	15	35	36	38	34	36	24	34
Accounts Receivable	4.42	5.34	5.67	6.05	10	7.33	9.24	9.86
Inventories, net	3.79	2.37	2.06	2.65	2.97	3.25	3.43	3.18
Other Current Assets	1.39	1.59	1.64	2.37	2.42	2.22	4.62	4.19
Plant, Property, & Equipment, net	0.42	0.59	1.12	1.42	1.44	2.05	2.58	2.26
Total Noncurrent Assets	15	16	18	22	22	22	22	16
Intangible Assets	15	15	15	16	16	17	17	11
Other Noncurrent Operating Assets	0.80	1.67	2.53	6.75	6.10	5.82	5.58	5.06
Total Liabilities & Shareholders' Equity	41	61	64	73	74	74	66	70
Total Liabilities	52	60	66	79	74	73	63	55
Total Current Liabilities	33	45	52	59	61	64	57	50
Accounts Payable	9.64	12	15	16	16	24	20	22
Accrued Expenses	15	15	15	21	19	15	22	15
Current Deferred Revenue	6.24	13	15	16	15	12	14	12
Other Current Liabilities	0.73	0.45	0.34	0.40	0.48	0.54	0.67	0.67
Total Noncurrent Liabilities	19	15	14	20	13	9.65	5.95	5.50
Other Noncurrent Operating Liabilities	0.43	1.41	2.44	6.61	6.29	6.13	5.95	5.50
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-11	1.30	-2.06	-5.96	-0.39	0.38	3.37	15
Total Preferred & Common Equity	-13	-0.85	-4.21	-7.72	-2.33	-1.78	1.31	15
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-13	-0.85	-4.21	-7.72	-2.33	-1.78	1.31	15
Common Stock	197	221	225	228	233	237	249	253
Retained Earnings	-210	-222	-229	-235	-236	-238	-248	-238
Treasury Stock	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16

This table displays calculated financial ratios and metrics derived from LifeMD's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-11.65%	70.67%	329.79%	-29.72%	126.09%	49.79%	199.10%	149.04%	28.16%	28.15%	39.27%
EBITDA Growth	-84.82%	47.49%	-422.26%	44.44%	-143.63%	-74.35%	-2,002.00%	2.24%	28.30%	80.96%	17.26%
EBIT Growth	-67.69%	44.56%	-347.98%	38.24%	-183.40%	-77.55%	-1,483.77%	-0.83%	25.47%	66.65%	-11.43%
NOPAT Growth	2.84%	50.61%	-347.98%	-4.57%	-67.39%	-40.54%	-1,900.94%	6.09%	19.99%	66.65%	-11.43%
Net Income Growth	-71.65%	65.42%	-668.25%	0.40%	-11.62%	-159.41%	-1,615.42%	-1.32%	26.59%	60.38%	-4.99%
EPS Growth	-100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	112.91%	-982.57%	-38.22%	-100.34%	-10.81%	127.76%	-4,925.47%	-172.72%	30.68%	138.46%	98.56%
Free Cash Flow Firm Growth	62.93%	-192.45%	-4.05%	-266.99%	-20.07%	114.85%	-11,545.49%	2.71%	-17.63%	75.17%	101.02%
Invested Capital Growth	-564.48%	125.56%	-803.91%	219.44%	119.79%	-260.21%	-548.90%	-67.49%	45.18%	-10.13%	-122.20%
Revenue Q/Q Growth	-0.12%	21.26%	13.24%	-4.75%	19.92%	16.43%	31.57%	18.54%	0.59%	12.33%	10.05%
EBITDA Q/Q Growth	32.44%	-178.94%	-56.03%	45.25%	-0.11%	-40.51%	-130.81%	21.22%	9.54%	54.37%	37.78%
EBIT Q/Q Growth	29.69%	-92.36%	-59.33%	42.75%	-15.77%	-29.32%	-122.29%	20.10%	7.05%	36.14%	16.50%
NOPAT Q/Q Growth	21.09%	-92.36%	-59.33%	30.36%	-15.77%	-2.36%	-122.29%	25.58%	7.05%	36.14%	16.50%
Net Income Q/Q Growth	-18.71%	-2.48%	-94.10%	31.13%	-16.27%	-10.89%	-119.84%	20.40%	12.50%	31.89%	15.58%
EPS Q/Q Growth	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	124.12%	-438.35%	-24.93%	-33.55%	8.60%	177.64%	-123.15%	2.10%	14.40%	675.36%	-19.14%
Free Cash Flow Firm Q/Q Growth	59.77%	-275.90%	46.63%	-43.94%	1.92%	151.19%	-179.10%	29.32%	13.43%	19.38%	-97.98%
Invested Capital Q/Q Growth	-56.02%	146.06%	-271.31%	437.85%	11.97%	-126.96%	-29.39%	-16.78%	-207.46%	-30.99%	18.14%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	75.80%	79.67%	39.04%	42.80%	76.02%	79.75%	76.24%	80.62%	84.32%	87.61%	88.67%
EBITDA Margin	-58.25%	-17.92%	-21.78%	-17.22%	-18.55%	-21.60%	-151.78%	-59.58%	-33.33%	-4.95%	-2.94%
Operating Margin	-74.34%	-21.51%	-22.42%	-33.36%	-24.70%	-23.18%	-155.04%	-58.47%	-36.50%	-9.50%	-7.60%
EBIT Margin	-66.23%	-21.51%	-22.42%	-19.71%	-24.70%	-29.28%	-155.04%	-62.77%	-36.50%	-9.50%	-7.60%
Profit (Net Income) Margin	-64.48%	-13.06%	-23.35%	-33.09%	-16.34%	-28.30%	-162.29%	-66.03%	-37.82%	-11.69%	-8.82%
Tax Burden Percent	96.40%	92.34%	100.00%	88.34%	56.42%	96.64%	100.20%	100.01%	100.81%	102.46%	102.19%
Interest Burden Percent	100.99%	65.76%	104.14%	190.11%	117.24%	100.00%	104.47%	105.18%	102.79%	120.17%	113.51%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-2,618.30%	-223.03%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-2,251.32%	-327.31%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	1,685.03%	34.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-1,644.91%	-767.53%	1,353.69%	-933.27%	-188.56%	2,279.95%	6,204.43%	-490.64%	-486.36%	2,051.24%	-2,462.99%
Cash Return on Invested Capital (CROIC)	0.00%	-873.54%	0.00%	-396.77%	-297.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-130.18%	-84.09%	-189.73%	-70.66%	-105.99%	-120.44%	-686.32%	-184.12%	-114.96%	-34.44%	-24.66%
Return on Assets (ROA)	-126.74%	-51.06%	-197.58%	-118.66%	-70.11%	-116.40%	-718.43%	-193.68%	-119.12%	-42.40%	-28.61%
Return on Common Equity (ROCE)	-1,644.91%	729.20%	1,910.61%	-1,882.71%	-232.62%	666.56%	10,462.86%	-401.15%	-298.01%	9,305.63%	3,207.37%
Return on Equity Simple (ROE_SIMPLE)	330.10%	-159.11%	344.42%	-138.16%	-151.51%	357.04%	2,629.32%	-269.67%	395.07%	-508.91%	341.42%
Net Operating Profit after Tax (NOPAT)	-0.37	-0.18	-0.82	-0.86	-1.44	-2.02	-40	-38	-30	-10	-11
NOPAT Margin	-52.04%	-15.06%	-15.70%	-23.35%	-17.29%	-16.22%	-108.53%	-40.93%	-25.55%	-6.65%	-5.32%
Net Nonoperating Expense Percent (NNEP)	-87.41%	26.83%	-734.60%	-366.98%	104.28%	-1,340.83%	-461.37%	-93.88%	-68.86%	-95.89%	-47.06%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-42.58%	-79.12%
Cost of Revenue to Revenue	24.20%	20.33%	60.96%	57.20%	23.98%	20.25%	23.76%	19.38%	15.68%	12.39%	11.33%
SG&A Expenses to Revenue	63.85%	36.62%	28.82%	31.58%	33.70%	29.62%	125.36%	49.20%	49.32%	43.02%	43.30%
R&D to Revenue	0.00%	1.96%	0.00%	0.00%	1.45%	1.79%	1.20%	1.02%	2.50%	3.97%	4.48%
Operating Expenses to Revenue	150.13%	101.19%	61.47%	76.16%	100.72%	102.92%	231.28%	139.09%	120.82%	97.11%	96.27%
Earnings before Interest and Taxes (EBIT)	-0.47	-0.26	-1.17	-0.73	-2.06	-3.65	-58	-58	-43	-14	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-0.42	-0.22	-1.14	-0.63	-1.54	-2.69	-57	-55	-40	-7.56	-6.25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	10.51	0.00	0.00	5.21	0.00	89.82	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	1.13	0.49	3.44	1.27	0.51	2.06	1.01
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	10.63	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	1.13	0.46	3.25	0.86	0.54	1.98	0.94
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	22.71	0.00	0.00	0.00	34.24	11.37
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	20.00	0.00	0.00	0.00	0.00	2,112.60
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.20	0.55	-0.57	0.27	0.30	-0.72	-0.95	0.00	-0.38	3.28	-4.53
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.22	-2.44
Financial Leverage	-3.63	-4.37	0.60	-0.75	-0.11	0.73	4.46	-1.99	-2.29	9.23	-20.76
Leverage Ratio	12.98	15.03	-6.85	7.86	2.69	-19.59	-8.64	2.53	4.08	-48.38	86.10
Compound Leverage Factor	13.11	9.88	-7.14	14.95	3.15	-19.59	-9.02	2.66	4.20	-58.13	97.74
Debt to Total Capital	-24.22%	35.59%	-132.83%	21.19%	23.18%	-259.05%	-1,827.58%	0.25%	-62.05%	76.63%	128.32%
Short-Term Debt to Total Capital	-24.22%	35.59%	-132.83%	21.19%	23.18%	-259.05%	-1,827.58%	0.25%	-62.05%	1.38%	59.12%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	75.26%	69.20%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	28.80%	4.22%	-32.78%	-7.31%	44.85%	-3,471.89%	11.90%	-90.73%	8.65%	10.08%
Common Equity to Total Capital	124.22%	35.62%	228.61%	111.59%	84.12%	314.20%	5,399.46%	87.86%	252.78%	14.71%	-38.40%
Debt to EBITDA	-0.07	-0.46	-0.18	-0.26	-0.16	-0.30	-0.01	0.00	-0.07	-2.42	-2.93
Net Debt to EBITDA	0.12	0.61	-0.02	-0.04	-0.04	0.11	0.15	0.75	0.03	1.97	2.67
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.37	-1.58
Debt to NOPAT	-0.07	-0.54	-0.25	-0.19	-0.17	-0.40	-0.02	0.00	-0.09	-1.80	-1.62
Net Debt to NOPAT	0.13	0.72	-0.03	-0.03	-0.05	0.14	0.21	1.09	0.04	1.47	1.48
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.77	-0.87
Altman Z-Score	0.00	0.00	0.00	0.00	-2.57	-6.24	-14.56	-2.49	-11.17	0.39	-0.88
Noncontrolling Interest Sharing Ratio	0.00%	195.01%	-41.14%	-101.73%	-23.36%	70.76%	-68.64%	18.24%	38.73%	-353.66%	230.22%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.44	1.68	0.69	1.97	1.35	0.69	0.89	1.97	0.36	1.22	0.81
Quick Ratio	0.30	1.45	0.55	0.42	0.23	0.30	0.73	1.85	0.22	1.10	0.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-0.14	-0.42	-0.44	-1.60	-1.92	0.29	-33	-32	-37	-9.28	0.09
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-13,375.17%	-6,255.62%	4,327.59%	1,174.71%
Free Cash Flow to Firm to Interest Expense	-30.62	-11.19	-8.98	-2.45	-5.43	0.00	-12.65	-10.53	-30.84	-3.18	0.04
Operating Cash Flow to Interest Expense	7.14	-7.88	-8.39	-1.25	-2.56	0.00	-4.70	-10.96	-18.91	3.02	8.03
Operating Cash Flow Less CapEx to Interest Expense	7.14	-7.88	-8.39	-1.25	-1.45	0.00	-4.70	-11.04	-19.22	2.95	7.34
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.97	3.91	8.46	3.59	4.29	4.11	4.43	2.93	3.15	3.63	3.25
Accounts Receivable Turnover	15.45	14.39	17.42	12.80	73.26	126.91	68.10	93.92	62.41	37.61	31.49
Inventory Turnover	2.72	4.86	28.86	5.01	2.34	2.56	8.00	12.49	7.02	5.85	8.66
Fixed Asset Turnover	9.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00	335.19	320.23	217.29
Accounts Payable Turnover	0.75	1.12	6.94	3.58	3.09	1.29	1.17	1.70	1.95	1.78	1.78
Days Sales Outstanding (DSO)	23.62	25.37	20.95	28.51	4.98	2.88	5.36	3.89	5.85	9.70	11.59
Days Inventory Outstanding (DIO)	134.30	75.17	12.65	72.92	155.77	142.56	45.60	29.22	52.01	62.41	42.14
Days Payable Outstanding (DPO)	485.34	325.41	52.60	101.84	118.06	283.30	312.94	215.03	187.37	204.62	205.44
Cash Conversion Cycle (CCC)	-327.42	-224.88	-19.00	-0.41	42.70	-137.87	-261.97	-181.92	-129.51	-132.51	-151.71
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.19	0.05	-0.34	0.40	0.89	-1.42	-9.22	-15	-8.47	-9.33	-21
Invested Capital Turnover	-9.69	-17.44	-36.14	112.11	12.90	-46.69	-7.01	-7.53	-9.96	-17.15	-14.14
Increase / (Decrease) in Invested Capital	-0.23	0.24	-0.39	0.74	0.48	-2.31	-7.80	-6.22	6.98	-0.86	-11
Enterprise Value (EV)	0.00	0.00	0.00	0.00	9.43	5.71	121	80	64	302	199
Market Capitalization	0.00	0.00	0.00	0.00	9.44	6.14	128	118	61	315	214
Book Value per Share	$0.00	$0.00	($0.01)	$0.02	$0.02	($0.02)	($0.12)	$0.74	($0.36)	$0.09	($0.13)
Tangible Book Value per Share	$0.00	$0.00	($0.01)	$0.02	$0.00	($0.03)	($0.15)	$0.64	($0.77)	($0.30)	($0.49)
Total Capital	-0.11	0.28	-0.16	0.79	1.07	-0.31	-0.04	26	-4.51	24	14
Total Debt	0.03	0.10	0.21	0.17	0.25	0.81	0.78	0.06	2.80	18	18
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18	9.89
Net Debt	-0.05	-0.13	0.02	0.03	0.07	-0.29	-8.40	-41	-1.16	-15	-17
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	-0.39	0.00	0.00	0.25	0.37	0.20	1.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.22	0.05	-0.34	0.65	0.48	-1.52	-9.92	-19	-21	-25	-38
Debt-free Net Working Capital (DFNWC)	-0.14	0.28	-0.16	0.79	0.66	-0.41	-0.74	22	-17	8.15	-3.08
Net Working Capital (NWC)	-0.17	0.18	-0.36	0.62	0.41	-1.23	-1.52	22	-20	7.82	-12
Net Nonoperating Expense (NNE)	0.09	-0.02	0.40	0.36	-0.08	1.51	20	23	15	7.70	7.43
Net Nonoperating Obligations (NNO)	-0.05	-0.13	0.02	-0.22	0.07	-0.29	-8.40	-41	-1.16	-15	-17
Total Depreciation and Amortization (D&A)	0.06	0.04	0.03	0.09	0.51	0.96	1.21	2.96	3.77	6.93	9.89
Debt-free, Cash-free Net Working Capital to Revenue	-30.57%	3.94%	-6.45%	17.63%	5.77%	-12.19%	-26.60%	-20.64%	-17.83%	-16.39%	-17.93%
Debt-free Net Working Capital to Revenue	-20.00%	23.05%	-2.97%	21.47%	7.93%	-3.32%	-1.99%	23.86%	-14.50%	5.34%	-1.45%
Net Working Capital to Revenue	-23.81%	14.85%	-6.91%	16.92%	4.96%	-9.85%	-4.07%	23.79%	-16.85%	5.13%	-5.42%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	$0.00	($0.03)	($0.03)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	30.73M	32.01M	33.48M	41.74M	44.19M	49.49M	14.28M	27.01M	30.98M	33.91M	41.20M
Adjusted Diluted Earnings per Share	($0.02)	$0.00	($0.03)	($0.03)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	30.73M	32.01M	33.48M	41.74M	44.19M	49.49M	14.28M	27.01M	30.98M	33.91M	41.20M
Adjusted Basic & Diluted Earnings per Share	($0.02)	$0.00	($0.03)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	30.37M	30.81M	36.90M	41.74M	46.88M	54.14M	25.91M	30.83M	31.89M	40.37M	44.58M
Normalized Net Operating Profit after Tax (NOPAT)	-0.37	-0.18	-0.82	-0.86	-1.44	-2.02	-40	-38	-24	-10	-11
Normalized NOPAT Margin	-52.04%	-15.06%	-15.70%	-23.35%	-17.29%	-16.22%	-108.53%	-40.93%	-20.34%	-6.65%	-5.32%
Pre Tax Income Margin	-66.89%	-14.15%	-23.35%	-37.46%	-28.96%	-29.28%	-161.96%	-66.02%	-37.52%	-11.41%	-8.63%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-101.00	-7.00	-24.16	-1.11	-5.80	0.00	-22.39	-19.31	-35.83	-4.96	-7.40
NOPAT to Interest Expense	-79.35	-4.90	-16.92	-1.32	-4.06	0.00	-15.67	-12.59	-25.08	-3.47	-5.18
EBIT Less CapEx to Interest Expense	-101.00	-7.00	-24.16	-1.11	-4.70	0.00	-22.39	-19.39	-36.13	-5.03	-8.08
NOPAT Less CapEx to Interest Expense	-79.35	-4.90	-16.92	-1.32	-2.96	0.00	-15.67	-12.67	-25.38	-3.54	-5.86
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	111.88%	17.98%	5.20%	11.49%	-2.52%	-0.26%	-1.66%	-7.22%	-18.22%	-20.72%
Augmented Payout Ratio	0.00%	105.10%	10.86%	-1.09%	11.49%	-2.52%	-0.26%	-1.66%	-7.22%	-18.22%	-20.72%

This table displays calculated financial ratios and metrics derived from LifeMD's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
DEI Shares Outstanding	36,032,740.00	37,978,804.00	40,366,047.00	42,289,990.00	43,068,867.00	-	44,583,688.00	45,447,604.00	47,417,393.00	48,135,885.00
DEI Adjusted Shares Outstanding	36,032,740.00	37,978,804.00	40,366,047.00	42,289,990.00	43,068,867.00	-	44,583,688.00	45,447,604.00	47,417,393.00	48,135,885.00
DEI Earnings Per Adjusted Shares Outstanding	-0.19	-0.12	-0.19	-0.18	-0.13	-	-0.02	-0.06	-0.10	-0.20
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	22.93%	59.53%	33.26%	40.94%	37.96%	43.23%	15.28%	22.81%	12.95%	-1.42%
EBITDA Growth	53.51%	98.57%	-174.94%	-21.44%	51.40%	2,911.96%	115.36%	151.49%	178.87%	-1,236.28%
EBIT Growth	35.33%	79.06%	-116.32%	-28.80%	12.54%	146.89%	80.85%	85.62%	50.72%	-655.60%
NOPAT Growth	35.33%	79.06%	-116.32%	-28.80%	12.54%	166.99%	80.85%	85.62%	50.72%	-655.60%
Net Income Growth	26.60%	72.16%	-93.14%	-16.05%	9.38%	107.28%	105.23%	77.04%	25.71%	-2,649.11%
EPS Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-900.00%
Operating Cash Flow Growth	138.77%	390.17%	299.02%	-2.25%	522.36%	-72.55%	-41.02%	90.31%	-102.20%	-85.51%
Free Cash Flow Firm Growth	107.57%	95.35%	209.75%	1,597.62%	1,219.76%	1,975.07%	-101.80%	-98.48%	-140.75%	-2,178.51%
Invested Capital Growth	-158.51%	-10.13%	-330.41%	-150.34%	-255.57%	-122.20%	-4.39%	-3.81%	19.34%	-18.86%
Revenue Q/Q Growth	7.42%	16.18%	-1.60%	14.76%	5.15%	20.34%	-20.80%	-5.30%	-3.29%	0.00%
EBITDA Q/Q Growth	14.59%	95.27%	-2,946.48%	1.38%	65.82%	280.69%	-83.36%	-61.95%	-47.64%	0.00%
EBIT Q/Q Growth	6.66%	52.48%	-184.19%	-2.18%	36.62%	121.73%	-216.05%	-135.66%	-117.17%	0.00%
NOPAT Q/Q Growth	6.66%	52.48%	-184.19%	-2.18%	36.62%	131.04%	-181.24%	-124.96%	-117.17%	0.00%
Net Income Q/Q Growth	10.32%	39.01%	-106.35%	-2.83%	29.98%	104.28%	48.31%	-181.90%	-126.57%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	-76.83%	430.90%	-8.95%	-12.73%	47.54%	-74.72%	95.64%	181.56%	-101.70%	0.00%
Free Cash Flow Firm Q/Q Growth	337.08%	-156.75%	1,264.25%	-4.39%	108.93%	-16.76%	-101.12%	-96.53%	-5,701.94%	0.00%
Invested Capital Q/Q Growth	9.17%	-30.99%	-68.02%	-25.23%	-29.01%	18.14%	21.06%	-24.53%	-0.24%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.62%	88.06%	89.58%	90.08%	90.59%	85.32%	84.01%	88.06%	87.69%	88.19%
EBITDA Margin	-7.13%	-0.29%	-9.00%	-7.73%	-2.51%	5.71%	1.20%	3.24%	1.76%	-13.82%
Operating Margin	-11.83%	-4.84%	-13.98%	-12.45%	-7.50%	1.58%	-2.32%	-1.46%	-3.27%	-17.80%
EBIT Margin	-11.83%	-4.84%	-13.98%	-12.45%	-7.50%	1.58%	-2.32%	-1.46%	-3.27%	-17.80%
Profit (Net Income) Margin	-13.68%	-7.18%	-15.06%	-13.50%	-8.99%	0.37%	0.68%	-2.52%	-5.91%	-17.69%
Tax Burden Percent	100.00%	115.32%	100.00%	100.00%	105.10%	58.07%	-21.15%	100.00%	104.99%	100.00%
Interest Burden Percent	115.62%	128.67%	107.74%	108.43%	113.98%	39.69%	139.23%	173.12%	172.02%	99.37%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	654.69%	2,051.24%	694.33%	358.62%	252.31%	-2,462.99%	-2,589.27%	583.82%	283.35%	0.00%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-43.40%	-17.55%	-47.97%	-44.71%	-25.56%	5.14%	-7.54%	-5.21%	-11.93%	0.00%
Return on Assets (ROA)	-50.18%	-26.04%	-51.69%	-48.47%	-30.62%	1.19%	2.22%	-9.02%	-21.54%	0.00%
Return on Common Equity (ROCE)	1,083.33%	9,305.63%	1,472.15%	591.48%	301.94%	3,207.37%	9,070.31%	2,084.87%	701.66%	0.00%
Return on Equity Simple (ROE_SIMPLE)	206.71%	0.00%	2,489.70%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.20	-1.52	-4.32	-4.41	-2.80	1.02	-0.83	-0.63	-1.38	-6.25
NOPAT Margin	-8.28%	-3.39%	-9.79%	-8.71%	-5.25%	1.58%	-1.63%	-1.02%	-2.29%	-12.46%
Net Nonoperating Expense Percent (NNEP)	-222.75%	-21.21%	-35.17%	-31.90%	-25.86%	-4.96%	7.14%	-4.88%	-10.10%	-10.40%
Return On Investment Capital (ROIC_SIMPLE)	-	-6.38%	-22.22%	-27.45%	-22.79%	7.13%	-4.59%	-4.00%	-40.93%	-41.57%
Cost of Revenue to Revenue	12.38%	11.94%	10.42%	9.92%	9.41%	14.68%	15.99%	11.94%	12.31%	11.81%
SG&A Expenses to Revenue	44.35%	43.00%	44.07%	45.72%	43.23%	39.75%	38.91%	38.29%	37.25%	42.85%
R&D to Revenue	3.88%	4.45%	4.73%	4.74%	4.90%	3.75%	3.65%	4.41%	4.73%	3.58%
Operating Expenses to Revenue	99.45%	92.90%	103.56%	102.53%	98.09%	83.74%	86.33%	89.51%	90.96%	105.99%
Earnings before Interest and Taxes (EBIT)	-4.57	-2.17	-6.17	-6.31	-4.00	1.02	-1.18	-0.91	-1.97	-8.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.75	-0.13	-3.97	-3.92	-1.34	3.67	0.61	2.02	1.06	-6.93
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	89.82	0.00	0.00	0.00	0.00	0.00	0.00	244.99	11.56
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	44.28
Price to Revenue (P/Rev)	1.66	2.06	2.54	1.63	1.17	1.01	1.11	2.52	1.28	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.70	1.98	2.45	1.54	1.08	0.94	1.04	2.45	1.19	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	67.05	26.45	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	202.85	34.24	24.05	16.62	9.39	11.37	14.86	30.82	23.76	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	40.46	2,112.60	0.00	0.00	0.00	45.15
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-1.74	3.28	13.97	-8.81	-3.06	-4.53	-46.92	40.48	0.00	0.00
Long-Term Debt to Equity	-1.70	3.22	10.83	-5.73	-2.17	-2.44	-17.36	9.20	0.00	0.00
Financial Leverage	0.23	9.23	2.19	1.24	0.90	-20.76	-36.34	22.84	16.68	-3.44
Leverage Ratio	-9.26	-48.38	-15.72	-8.09	-6.65	86.10	149.06	-81.92	-53.56	9.82
Compound Leverage Factor	-10.70	-62.25	-16.94	-8.78	-7.58	34.18	207.54	-141.81	-92.13	9.75
Debt to Total Capital	235.68%	76.63%	93.32%	112.81%	148.52%	128.32%	102.18%	97.59%	0.00%	0.00%
Short-Term Debt to Total Capital	5.22%	1.38%	20.95%	39.46%	43.00%	59.12%	64.37%	75.41%	0.00%	0.00%
Long-Term Debt to Total Capital	230.47%	75.26%	72.36%	73.34%	105.52%	69.20%	37.80%	22.18%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	19.43%	8.65%	11.03%	13.35%	14.38%	10.08%	10.73%	13.65%	60.98%	0.00%
Common Equity to Total Capital	-155.11%	14.71%	-4.35%	-26.16%	-62.90%	-38.40%	-12.91%	-11.24%	39.02%	100.00%
Debt to EBITDA	-1.16	-2.42	-1.80	-1.68	-1.95	-2.93	-11.04	1.73	0.00	0.00
Net Debt to EBITDA	-0.24	1.97	1.68	1.63	2.07	2.67	9.56	-2.32	0.00	0.00
Long-Term Debt to EBITDA	-1.14	-2.37	-1.40	-1.09	-1.38	-1.58	-4.08	0.39	0.00	0.00
Debt to NOPAT	-1.21	-1.80	-1.46	-1.35	-1.40	-1.62	-2.36	-10.88	0.00	0.00
Net Debt to NOPAT	-0.25	1.47	1.36	1.31	1.48	1.48	2.04	14.59	0.00	0.00
Long-Term Debt to NOPAT	-1.19	-1.77	-1.13	-0.88	-0.99	-0.87	-0.87	-2.47	0.00	0.00
Altman Z-Score	-1.87	1.09	1.41	-0.05	-0.51	-0.10	0.23	3.60	1.27	-3.25
Noncontrolling Interest Sharing Ratio	-65.47%	-353.66%	-112.02%	-64.93%	-19.67%	230.22%	450.30%	-257.11%	-147.63%	13.22%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.77	1.22	0.99	0.87	0.83	0.81	0.82	0.77	0.73	1.04
Quick Ratio	0.61	1.10	0.91	0.80	0.74	0.72	0.73	0.69	0.58	0.89
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	1.17	-0.66	7.71	7.37	15	12	-0.14	0.11	-6.27	-3.17
Operating Cash Flow to CapEx	3,556.21%	5,225.94%	2,962.64%	707.07%	1,495.74%	695.78%	2,610.39%	1,085.71%	-18.46%	422.73%
Free Cash Flow to Firm to Interest Expense	1.63	-1.06	16.14	13.87	27.56	20.22	-0.30	0.17	-4.42	0.00
Operating Cash Flow to Interest Expense	1.51	9.18	10.89	8.54	11.99	2.55	6.62	13.03	-0.10	0.00
Operating Cash Flow Less CapEx to Interest Expense	1.47	9.00	10.52	7.33	11.19	2.19	6.36	11.83	-0.67	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	3.67	3.63	3.43	3.59	3.41	3.25	3.25	3.57	3.64	0.00
Accounts Receivable Turnover	39.04	37.61	39.54	38.19	36.86	31.49	28.23	37.78	33.02	0.00
Inventory Turnover	4.72	5.85	6.70	6.86	6.21	8.66	10.34	11.49	10.83	0.00
Fixed Asset Turnover	283.46	320.23	312.02	227.43	209.18	217.29	216.51	154.74	126.08	0.00
Accounts Payable Turnover	1.72	1.78	2.00	1.60	1.57	1.78	1.97	1.55	1.86	0.00
Days Sales Outstanding (DSO)	9.35	9.70	9.23	9.56	9.90	11.59	12.93	9.66	11.06	0.00
Days Inventory Outstanding (DIO)	77.37	62.41	54.47	53.18	58.75	42.14	35.31	31.77	33.70	0.00
Days Payable Outstanding (DPO)	211.74	204.62	182.62	227.59	232.80	205.44	185.60	235.28	196.42	0.00
Cash Conversion Cycle (CCC)	-125.03	-132.51	-118.92	-164.85	-164.15	-151.71	-137.36	-193.86	-151.66	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-7.12	-9.33	-16	-20	-25	-21	-16	-20	-20	-19
Invested Capital Turnover	-27.51	-17.15	-16.94	-12.99	-11.90	-14.14	-13.69	-12.28	-11.04	0.00
Increase / (Decrease) in Invested Capital	-4.37	-0.86	-12	-12	-18	-11	-0.69	-0.75	4.90	-3.09
Enterprise Value (EV)	231	302	400	275	208	199	229	600	300	139
Market Capitalization	225	315	415	290	226	214	243	619	322	174
Book Value per Share	($0.35)	$0.09	($0.02)	($0.10)	($0.18)	($0.13)	($0.05)	($0.04)	$0.03	$0.32
Tangible Book Value per Share	($0.76)	($0.30)	($0.39)	($0.46)	($0.54)	($0.49)	($0.41)	($0.41)	($0.33)	$0.08
Total Capital	8.17	24	19	16	12	14	18	16	3.37	15
Total Debt	19	18	18	18	18	18	18	15	0.00	0.00
Total Long-Term Debt	19	18	14	12	13	9.89	6.82	3.52	0.00	0.00
Net Debt	3.97	-15	-17	-18	-19	-17	-16	-21	-24	-34
Capital Expenditures (CapEx)	0.03	0.11	0.18	0.64	0.45	0.23	0.12	0.80	0.80	0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-22	-25	-31	-36	-43	-38	-34	-39	-39	-32
Debt-free Net Working Capital (DFNWC)	-7.21	8.15	3.81	-0.23	-5.02	-3.08	0.68	-2.55	-16	2.11
Net Working Capital (NWC)	-7.64	7.82	-0.27	-6.58	-10	-12	-11	-15	-16	2.11
Net Nonoperating Expense (NNE)	2.08	1.70	2.33	2.42	1.99	0.78	-1.18	0.94	2.18	2.62
Net Nonoperating Obligations (NNO)	3.97	-15	-17	-18	-19	-17	-16	-21	-24	-34
Total Depreciation and Amortization (D&A)	1.81	2.04	2.20	2.39	2.66	2.65	1.79	2.92	3.03	2.00
Debt-free, Cash-free Net Working Capital to Revenue	-16.57%	-16.39%	-19.14%	-20.16%	-22.08%	-17.93%	-15.38%	-15.79%	-15.59%	0.00%
Debt-free Net Working Capital to Revenue	-5.31%	5.34%	2.33%	-0.13%	-2.60%	-1.45%	0.31%	-1.04%	-6.17%	0.00%
Net Working Capital to Revenue	-5.62%	5.13%	-0.16%	-3.69%	-5.34%	-5.42%	-4.99%	-5.91%	-6.17%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	34.47M	33.91M	39.24M	41.30M	42.02M	41.20M	43.14M	44.40M	46.16M	47.34M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	34.47M	33.91M	39.24M	41.30M	42.02M	41.20M	45.58M	44.40M	46.16M	47.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	37.98M	40.37M	42.29M	43.07M	43.31M	44.58M	45.45M	47.42M	48.14M	48.36M
Normalized Net Operating Profit after Tax (NOPAT)	-3.20	-1.52	-4.32	-4.41	-2.80	0.71	-0.83	-0.63	-1.38	-6.25
Normalized NOPAT Margin	-8.28%	-3.39%	-9.79%	-8.71%	-5.25%	1.11%	-1.63%	-1.02%	-2.29%	-12.46%
Pre Tax Income Margin	-13.68%	-6.23%	-15.06%	-13.50%	-8.55%	0.63%	-3.23%	-2.52%	-5.63%	-17.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.40	-3.49	-12.92	-11.86	-7.15	1.66	-2.55	-1.37	-1.39	0.00
NOPAT to Interest Expense	-4.48	-2.44	-9.04	-8.31	-5.01	1.66	-1.78	-0.96	-0.97	0.00
EBIT Less CapEx to Interest Expense	-6.44	-3.66	-13.29	-13.07	-7.96	1.29	-2.80	-2.57	-1.95	0.00
NOPAT Less CapEx to Interest Expense	-4.52	-2.62	-9.41	-9.51	-5.81	1.29	-2.04	-2.16	-1.53	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-12.41%	-18.22%	-15.44%	-14.78%	-17.42%	-20.72%	-32.77%	-84.16%	-110.20%	0.00%
Augmented Payout Ratio	-12.41%	-18.22%	-15.44%	-14.78%	-17.42%	-20.72%	-32.77%	-84.16%	-110.20%	0.00%

Financials Breakdown Chart

LifeMD Financials - Frequently Asked Questions

According to the most recent income statement we have on file, LifeMD's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

LifeMD's net income appears to be on an upward trend, with a most recent value of -$18.73 million in 2024, rising from -$460.49 thousand in 2014. The previous period was -$17.84 million in 2023. Find out what analysts predict for LifeMD in the coming months.

LifeMD's total operating income in 2024 was -$16.14 million, based on the following breakdown:

Total Gross Profit: $188.39 million
Total Operating Expenses: $204.53 million

Over the last 10 years, LifeMD's total revenue changed from $714.16 thousand in 2014 to $212.45 million in 2024, a change of 29,648.9%.

LifeMD's total liabilities were at $47.25 million at the end of 2025, a 43.5% decrease from 2024, and a 17,566.6% increase since 2015.

In the past 10 years, LifeMD's cash and equivalents has ranged from $141.38 thousand in 2017 to $41.33 million in 2021, and is currently $36.79 million as of their latest financial filing in 2025.

Over the last 10 years, LifeMD's book value per share changed from 0.00 in 2014 to -0.13 in 2024, a change of 2,715.6%.

Related Companies

Financial statements for NASDAQ:LFMD last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Financials

Financials Breakdown Chart

LifeMD Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Financials

Annual Income Statements for LifeMD

Quarterly Income Statements for LifeMD

Annual Cash Flow Statements for LifeMD

Quarterly Cash Flow Statements for LifeMD

Annual Balance Sheets for LifeMD

Quarterly Balance Sheets for LifeMD

Annual Metrics And Ratios for LifeMD

Quarterly Metrics And Ratios for LifeMD

Financials Breakdown Chart

LifeMD Financials - Frequently Asked Questions

When does LifeMD's financial year end?

How has LifeMD's net income changed over the last 10 years?

What is LifeMD's operating income?

How has LifeMD's revenue changed over the last 10 years?

How much debt does LifeMD have?

How much cash does LifeMD have?

How has LifeMD's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools